GAITHERSBURG, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq:ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the signing of a definitive agreement to sell its SimpliDerm® human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million. Elutia will receive $8 million in cash at closing, along with up to $3 million in technology transfer and commercial milestone payments over the next 18 months. Closing is expected to occur in the second half of 2026, subject to customary closing conditions.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Medical%20lab%20microscope%20chemistry%20biology%20test%20by%20Shutter2U%20via%20Adobe%20Stock.jpeg)
/AI%20(artificial%20intelligence)/An%20aerial%20view%20of%20a%20data%20center%20cooling%20system%20by%20Sepia100%20via%20Adobe%20Stock.jpeg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
